

MOTIV[®]

Tyrocore Peripheral Vascular
Bioresorbable Scaffold

The Most Advanced BRS


World's Thinnest Bioresorbable Scaffold

Thin struts and best-in-class strength promote vessel healing to maintain patency

Reduced Strut Thickness



Size	Absorb ¹	Magmaris ¹	MOTIV
2.5 mm	157 μ m	n/a	95 μ m
3.0 mm	157 μ m	166 μ m	105 μ m
3.5 mm	157 μ m	166 μ m	115 μ m

Best-in-Class Radial Strength²




A New Era for BRS Deliverability

Full radiopacity for procedural accuracy




Lower Crossing Profile³



Higher Expansion Tolerance³




Limit of Expansion over Nominal, 3.0 mm Scaffolds



Improved ease-of-use during implant procedure

Rapid Vessel Healing, Benign Resorption

Demonstrated with Fantom BRS



MOTIV Performance Characteristics

Characteristic	MOTIV	Magmaris	Absorb
Scaffold material	Tyrocore	Magnesium alloy ³	PLLA ³
Drug coating	Sirolimus + Tyrocore	Sirolimus + PLLA ³	Sirolimus + PDLLA ³
Strut thickness	2.5 mm, 95 μ m 3.0 mm, 105 μ m 3.5 mm, 115 μ m	166 μ m ¹	157 μ m ¹
Crossing profile	1.3 mm	1.5 mm ³	1.44 mm ³
Delivery	Single-step inflation	Single-step inflation	Multi-step inflation ³
Radial strength²	0.22 N/mm	0.17 N/mm	0.14 N/mm
Recoil²	2.0%	6.8%	2.3%
Max expansion over nominal	+0.75 mm, 2.5–3.0 mm diam +0.5 mm, 3.5 mm diam	+0.6 mm ³	+0.5 mm ³
Resorption profile	Vessel uncaged in 1 year Resorption in ~4 years	~40% mass loss at 90 days ~95% mass loss at 1 year ³	Loss of mechanical support in 9 months Resorption in 3 years ³

MOTIV Ordering Information

MOTIV[®] Sirolimus-Eluting Bioresorbable Vascular Scaffold System

	12 mm	18 mm	24 mm	36 mm	48 mm	60 mm
2.5 mm	920025-12	920025-18	920025-24	920025-36	920025-48	920025-60
3.0 mm	920030-12	920030-18	920030-24	920030-36	920030-48	920030-60
3.5 mm	920035-12	920035-18	920035-24	920035-36	920035-48	920035-60

References

1. Ormiston, J. New BRS Platforms. Presented EBC Rotterdam 2016. Foin, N. Biomechanical Assessment of Bioresorbable Devices. Presented CRT 2017.
2. 3.0 mm diameter scaffolds. Tests performed by and data on file at REVA Medical.
3. Manufacturer reported data on file at REVA Medical.
4. Abizaid, A. New 24-month data from the FANTOM II clinical trial. EuroPCR 2018.
5. Abizaid, A. The FANTOM II study, first report for the 12-month clinical outcomes of the Fantom sirolimus-eluting bioresorbable scaffold. EuroPCR 2018.

REVA Medical European Authorized Representative: HealthLink Europe BV, De Tweeling 20-22, 5215 MC 's-Hertogenbosch, The Netherlands.

TEL: +31 73 303 2559, EMAIL: revamedical@healthlinkeurope.com

MOTIV is available in select countries that accept CE Mark. MOTIV not available in the U.S. or countries that do not accept CE Mark.

MOTIV and Tyrocore are trademarks of REVA Medical, LLC. REVA Medical, LLC, 5751 Copley Drive, San Diego, CA, 92111, United States of America.

Absorb is a trademark of Abbott. Magmaris is a trademark of Biotronik.

www.revamedical.com

©2018 REVA Medical, LLC. CC100098 Rev. A

REVA